WO2013032230A3 - Pharmaceutical angiogenic composition including a microrna-382 activator - Google Patents
Pharmaceutical angiogenic composition including a microrna-382 activator Download PDFInfo
- Publication number
- WO2013032230A3 WO2013032230A3 PCT/KR2012/006909 KR2012006909W WO2013032230A3 WO 2013032230 A3 WO2013032230 A3 WO 2013032230A3 KR 2012006909 W KR2012006909 W KR 2012006909W WO 2013032230 A3 WO2013032230 A3 WO 2013032230A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microrna
- activator
- pharmaceutical
- angiogenic composition
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to an angiogenic composition, and more particularly, to a pharmaceutical angiogenic composition including a microRNA-382 activator. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis. Therefore, provided in the present invention is the pharmaceutical angiogenic composition which includes the microRNA-382 activator, which is angiogenic and thus promotes cell proliferation, and can be valuably used in treating injuries, ischemic myocardial infarctions, or foot ischemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/240,530 US9051620B2 (en) | 2011-08-30 | 2012-08-29 | Pharmaceutical angiogenic composition including a microRNA-382 activator |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0086986 | 2011-08-30 | ||
KR20110086986 | 2011-08-30 | ||
KR10-2012-0094792 | 2012-08-29 | ||
KR1020120094792A KR20130024830A (en) | 2011-08-30 | 2012-08-29 | Pharmaceutical composition comprising microrna-382 activator for promoting angiogenic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013032230A2 WO2013032230A2 (en) | 2013-03-07 |
WO2013032230A3 true WO2013032230A3 (en) | 2013-05-10 |
Family
ID=47757053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/006909 WO2013032230A2 (en) | 2011-08-30 | 2012-08-29 | Pharmaceutical angiogenic composition including a microrna-382 activator |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013032230A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008014008A2 (en) * | 2006-07-28 | 2008-01-31 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
KR20100009268A (en) * | 2008-07-18 | 2010-01-27 | 국립암센터 | Anti-cancer composition comprising microrna molecules |
-
2012
- 2012-08-29 WO PCT/KR2012/006909 patent/WO2013032230A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008014008A2 (en) * | 2006-07-28 | 2008-01-31 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
KR20100009268A (en) * | 2008-07-18 | 2010-01-27 | 국립암센터 | Anti-cancer composition comprising microrna molecules |
Non-Patent Citations (2)
Title |
---|
KIM, MIN JEONG: "The roles of microRNA-382 induced by hypoxia in angiogenesis", MASTER'S THESIS, KYUNKPOOK NATIONAL UNIVERSITY GRADUATE SCHOOL, June 2010 (2010-06-01) * |
SUAREZ ET AL.: "MicroRNAs as novel regulators of angiogenesis", CIRCULATION RESEARCH, vol. 104, 2009, pages 442 - 454, XP008108165, DOI: doi:10.1161/circresaha.108.191270 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013032230A2 (en) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
IN2014DN09782A (en) | ||
EA026892B9 (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
MX355304B (en) | Conformable personal care articles. | |
MA37400A1 (en) | Cyclil compounds are not heterogeneous as mek inhibitors | |
NZ595372A (en) | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | |
MX355295B (en) | Personal care article. | |
MX350541B (en) | Materials and methods for improving gastrointestinal function. | |
WO2011056021A3 (en) | Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis | |
MX2014012477A (en) | Pyrrolopyrazone inhibitors of tankyrase. | |
ECSP13013044A (en) | COMPOSITION THAT INCLUDES AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACILO (5-FU) AND IRINOCETAN (FOLFIRI) | |
IN2014DN06104A (en) | ||
GB201316021D0 (en) | Vitamin D composition | |
MX2020014208A (en) | Optimised subcutaneous therapeutic agents. | |
MX2015003343A (en) | Combined treatment with netrin-1 interfering drug and chemotherapeutic drug. | |
IN2012DE00497A (en) | ||
TR201009167A2 (en) | Pharmaceutical granules containing cephalosporin. | |
MX2021003230A (en) | Pharmaceutical compositions comprising meloxicam. | |
WO2011103382A3 (en) | Compositions and methods for inducing angiogenesis | |
WO2013032230A3 (en) | Pharmaceutical angiogenic composition including a microrna-382 activator | |
WO2014104989A8 (en) | Pharmaceutical compositions comprising aripiprazole | |
MX2014010749A (en) | Gynecologic composition to treat vulvar vestibulitis. | |
PH12015500262A1 (en) | Novel pyridine derivatives | |
WO2013025074A3 (en) | Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract | |
MX351093B (en) | Novel azetidine derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12828384 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14240530 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12828384 Country of ref document: EP Kind code of ref document: A2 |